BRÈVE

sur Bonyf NV

Proven Efficacy of Bonyf's Fast Pain-Relief Mouth Ulcer Cream

Ghent (Belgium), June 2024 - Bonyf NV, listed on Euronext Paris under the mnemonic MLBON, reaffirms its commitment to research and development. The company highlights the proven effectiveness of its unique fast pain-relief mouth ulcer cream, AphtoFix®. This product demonstrates Bonyf's dedication to advancing oral healthcare.

Bonyf's mouth ulcer cream is formulated with a proprietary blend of clinically proven ingredients. Notably, a recent clinical study published in the Journal of Dental Hygiene Science reveals significant results. Key findings include rapid pain relief from day one, an average healing rate within seven days, and a protective muco-adhesive barrier that isolates ulcers from the oral environment.

Jean-Pierre Bogaert, CEO of Bonyf, states, "This study underscores the exceptional efficacy of our mouth ulcer cream and our position as a leading R&D company." The cream is available for purchase through leading retailers in multiple countries. Further information on the product and Bonyf's research can be found at www.bonyf.com.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Bonyf NV